Stock MRKR MARKER THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Market Closed - Nasdaq
Other stock markets
 20:26:51 21/05/2024 BST 		5-day change 1st Jan Change
4.088 USD -2.67% Intraday chart for Marker Therapeutics, Inc. +2.71% -25.68%
05-15 Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M MT
04-30 Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Top Midday Gainers
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse
Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Marker Therapeutics Says Non-clinical Data Show MT-401 Inducing Anti-tumor Activity in Specific Setting
Marker Therapeutics Says Acute Myeloid Leukemia Treatment Candidate Granted Orphan Drug Designation in European Union
Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen-Specific T Cell Product Candidate, Mt-401
Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration
Cell Ready, LLC completed the acquisition of Certain Cell Manufacturing Assets of Marker Therapeutics, Inc.
Marker Therapeutics Says First Patient Dosed in Phase 1 Trial of Lymphoma Treatment
Sector Update: Health Care Stocks Advancing Late Wednesday
Sector Update: Health Care Stocks Higher in Afternoon Trading
Top Midday Gainers
Sector Update: Health Care Stocks Steady Premarket Wednesday
Sector Update: Health Care
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRKR Stock
  4. News Marker Therapeutics, Inc.
  5. Other languages